Compare ABR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABR | NVAX |
|---|---|---|
| Founded | 2003 | 1987 |
| Country | United States | United States |
| Employees | 653 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 1996 |
| Metric | ABR | NVAX |
|---|---|---|
| Price | $5.93 | $9.23 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 9 |
| Target Price | $9.90 | ★ $11.33 |
| AVG Volume (30 Days) | 4.0M | ★ 4.6M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | ★ 15.42% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.29 | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $5.69 | $6.20 |
| 52 Week High | $12.58 | $11.85 |
| Indicator | ABR | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 25.14 | 55.25 |
| Support Level | N/A | $9.14 |
| Resistance Level | $8.15 | $10.63 |
| Average True Range (ATR) | 0.33 | 0.61 |
| MACD | -0.25 | 0.18 |
| Stochastic Oscillator | 7.89 | 49.01 |
Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily, SFR, and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.